# Nurix Therapeutics

> Nurix Therapeutics is a clinical-stage biopharmaceutical company in San Francisco pioneering targeted protein degradation - medicines that destroy disease-causing proteins rather than merely blocking them. Built on its DELigase discovery engine that harnesses the cell's ubiquitin-proteasome system and DNA-encoded library screening, Nurix is advancing a pipeline of degraders and degrader antibody conjugates for cancer and autoimmune disease, led by the BTK degrader bexobrutideg (NX-5948). The company is partnered with Roche, Sanofi, Gilead, and Pfizer (via Seagen) and trades on Nasdaq under NRIX.

- **Founded:** 2009
- **Headquarters:** San Francisco, California, United States
- **Founders:** Michael Rape (Scientific Co-Founder (UC Berkeley professor)), John Kuriyan (Scientific Co-Founder (UC Berkeley professor)), Arthur Weiss (Scientific Co-Founder (UCSF professor))
- **Team size:** ~290 employees
- **Products:** Bexobrutideg (NX-5948), NX-1607, DELigase platform, Degrader Antibody Conjugates (DACs)
- **Notable:** First company founded specifically to pursue targeted protein degradation., Completed a $209M IPO on Nasdaq (NRIX) in July 2020., Secured a global collaboration with Roche worth up to $2.3 billion, including $700M cash up front, for bexobrutideg (June 2026).

## Products & services

- **Bexobrutideg (NX-5948)** — An investigational brain-penetrant, orally available small molecule degrader of BTK in a pivotal Phase 2 (DAYBreak CLL-201) for relapsed/refractory chronic lymphocytic leukemia, with a Phase 3 planned for mid-2026; partnered globally with Roche.
- **NX-1607** — An investigational oral inhibitor of the E3 ligase CBL-B for immuno-oncology, in a Phase 1 trial across a range of oncology indications.
- **DELigase platform** — Nurix's proprietary drug discovery engine combining DNA-encoded libraries, E3 ligase/ubiquitin biology and machine learning (DEL-AI) to design protein degraders and modulators.
- **Degrader Antibody Conjugates (DACs)** — A new class of cancer therapeutics that links a targeted protein degrader to an antibody for tumor-directed delivery, developed in partnership with Seagen (now Pfizer).

## Achievements

- First company founded specifically to pursue targeted protein degradation.
- Completed a $209M IPO on Nasdaq (NRIX) in July 2020.
- Secured a global collaboration with Roche worth up to $2.3 billion, including $700M cash up front, for bexobrutideg (June 2026).
- Built a multi-partner platform with Gilead, Sanofi and Pfizer.
- Advanced bexobrutideg into a pivotal Phase 2 with a Phase 3 planned for mid-2026.

## Latest updates

- **2026-06** — Announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg - $700M upfront, up to $2.3B in total deal value.
- **2026-05** — Reported first quarter fiscal 2026 financial results and corporate update.
- **2026-01** — Outlined 2026 goals focused on advancing bexobrutideg, including a planned mid-2026 Phase 3 confirmatory trial versus pirtobrutinib in relapsed/refractory CLL.

## Links

- Website: https://www.nurixtx.com
- LinkedIn: https://www.linkedin.com/company/nurixtx
- Twitter/X: https://twitter.com/Nurix_Tx

---

Profile page: https://yespress.io/nurix-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-20